Intraoperative opioids use for laryngeal squamous cell carcinoma surgery and recurrence: a retrospective study

Identification of risk factors associated with postoperative acute kidney injury after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a retrospective study

“…Age and diabetes-associated declines in glomerular filtration rate (GFR) and renal blood flow have been recognised for decades [29][30][31]. For instance, arterial thickening and glomerulopathic changes have also been observed in the kidneys of older donors and diabetic patients [32,33].…”

Intravenous opioid drug abuse as an independent risk factor for supraglottic squamous cell carcinoma—A case‐control study

“…The possible carcinogenic effect of opioids was further investigated in a completely different population, oncologic patients receiving pain‐relieving opiates. Previous studies suggested that intra‐operative administration of opioids in oncologic patients might be associated with recurrence . Zylla et al found that higher mu opioid receptor expression on tumour specimens and greater opioid requirements are associated with shorter progression‐free survival and overall survival in patients with metastatic prostate cancer.…”

“…Previous studies suggested that intraoperative administration of opioids in oncologic patients might be associated with recurrence. 15,16,26 Zylla et al 27 found that higher mu opioid receptor expression on tumour specimens and greater opioid requirements are associated with shorter progression-free survival and overall survival in patients with metastatic prostate cancer. The mu opioid receptor has been found in a wide range of tumours such as lung carcinoma, breast cancer, liver cancer and colon cancer.…”

“…Therefore, the relation between IVDA and SG‐SCC, in particular, has not been described until now. Recognising the relations between opioids and specific malignancies is important for several reasons: it can help identify high‐risk populations and also may have an important role in the management of these oncologic patients as current pain control in oncologic patients often includes opioid agents . Moreover, if indeed opioids contribute to the development of specific malignancies, anti‐opioids might serve as part of future treatments.…”

Opioids trigger breast cancer metastasis through E-Cadherin downregulation and STAT3 activation promoting epithelial-mesenchymal transition

“…Epidemiologic studies revealed that administering opioids after surgical tumor removal enhanced the risk of cancer recurrence or enhanced metastasis in BCa patients undergoing mastectomy and axillar clearance (3)(4)(5). In addition, opioid treatment of patients with advanced malignant tumors is associated with worse overall survival (6)(7)(8)(9).…”